Physician profile
Wilfred Kearse
NPI 1144232778
$5,267.64
in general payments reported to CMS, 2019-2025
46 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $349 · 2021: $974 · 2022: $812 · 2023: $1,002 · 2024: $555 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $621.04 | 2021-2025 | Jelmyto |
| Teleflex LLC | $374.64 | 2021-2025 | Urolift |
| Allergan, INC. | $355.27 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $307.01 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $249.13 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $226.22 | 2021-2025 | Prolaris |
| Neotract INC. | $215.35 | 2019-2020 | |
| Janssen Biotech, INC. | $209.66 | 2020-2025 | Erleada |
| Endo Pharmaceuticals INC. | $179.52 | 2022-2024 | Xiaflex, Aveed |
| Photocure INC | $157.34 | 2023-2025 | Cysview |
| Axonics, INC. | $145.96 | 2021-2024 | Axonics |
| Abbvie INC. | $145.93 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $129.59 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $127.39 | 2019-2024 | |
| Antares Pharma, INC. | $127.34 | 2019-2025 | Xyosted |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfred Kearse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.